Ardelyx (ARDX) Share-based Compensation (2013 - 2025)
Ardelyx (ARDX) posted Share-based Compensation of -$3.6 million for Q3 2025, up 56.57% on a QoQ basis from -$8.2 million in Q2 2025, and down 573.44% year-over-year from $753000.0 in Q3 2024.
Ardelyx (ARDX) Share-based Compensation (2013 - 2025) Analysis & Trends
Ardelyx's Share-based Compensation history runs 13 years deep, the most recent figure standing at -$3.6 million for Q3 2025.
- Quarterly Share-based Compensation fell 573.44% year-over-year to -$3.6 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (down 189.88% YoY) and the FY2025 annual result came in at $315000.0, down 68.81% from the prior year.
- Share-based Compensation was -$3.6 million for Q3 2025 at Ardelyx, up from -$8.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.1 million in Q1 2025 and bottomed at -$9.3 million in Q4 2023.
- A 5-year average of $192235.3 and a median of $1.4 million in 2021 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 152.98% — and 2025, when it sank 3293.77%.
- Ardelyx's Share-based Compensation stood at $1.4 million in 2021, then slumped by 127.58% to -$390000.0 in 2022, then tumbled by 2274.62% to -$9.3 million in 2023, then soared by 108.13% to $753000.0 in 2024, then tumbled by 573.44% to -$3.6 million in 2025.
- Business Quant data shows ARDX's Share-based Compensation at -$3.6 million in Q3 2025, -$8.2 million in Q2 2025, and $12.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Ardelyx | 1.24 Bn | 999.81 Mn | 89.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.57 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Jun 30, 2025 | -8.21 Mn |
| Jun 30, 2025 | -8.21 Mn |
| Mar 31, 2025 | 12.09 Mn |
| Mar 31, 2025 | 12.09 Mn |
| Sep 30, 2024 | 753,000.00 |
| Sep 30, 2024 | 753,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Dec 31, 2023 | -9.26 Mn |
| Dec 31, 2023 | -9.26 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | 2.91 Mn |
| Mar 31, 2023 | 2.91 Mn |
| Dec 31, 2022 | -390,000.00 |
| Dec 31, 2022 | -390,000.00 |